Astrasana and Clever Leaves Partner to Establish International Supply Agreement For Medical Cannabis Extracts in Czech Republic and Switzerland
plus
Actualités sur Medizin, Gesundheit
DEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
plusSchweizerischer Nationalfonds / Fonds national suisse
The age of blood stains says more about the crime
Bern (ots) - The composition of blood stains changes over the course of weeks and months. Forensic medicine hopes to make use of this fact in future to convict suspects - or to prove their innocence. The blood-stained paper lay on the roof terrace for almost a year, protected from the rain but otherwise exposed to the elements. Fortunately it wasn't evidence of a violent crime; no, the drops of blood were part of a ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Mosquitoes prefer cooler temperatures
Bern (ots) - Mosquitoes have thermal preferences. This is an important parameter to better predict outbreaks of diseases transmitted by these insects. "If they have a choice, when it's hot, mosquitoes hide in a cool place to rest," says Niels Verhulst, author of a study recently published in the journal Thermal Biology (*). The entomologist from the University of Zurich summarises the results of the experiment he ...
plusHuma named for its successful and innovative approach to clinical trials in new UK government review
New York and London (ots/PRNewswire) - - Huma's innovative approach to medical research cited in Lord James O'Shaughnessy's review for clinical trials improvement in the UK - The review is part of a new widespread policy approach to ignite the UK's life sciences sector - Innovating clinical trials using digital technologies such as Huma's platforms can make them more ...
plusDeep Breath Intelligence Teams with HTEC Group and Effectum Medical to Accelerate the Launch of CE-marked device under IVDD
Belgrade, Serbia (ots/PRNewswire) - Deep Breath Intelligence (DBI), a MedTech company unleashing the huge potential of exhaled breath analysis through machine learning, has selected HTEC Group and Effectum Medical as primary innovation facilitators to help them achieve greater speed in meeting both software and ...
plus
Debiopharm Partners with Genedata to Digitalize Translational Research
Basel, Switzerland (ots) - Pioneer in advancing tomorrow’s standard of care to cure cancer and infectious diseases, Debiopharm selects Genedata Profiler, an industry-leading digital platform for translational and reverse translational research, as the cornerstone of its research and development strategy. Genedata, the leading provider of enterprise software solutions ...
plusGrünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
plusEuropean study highlights need to improve the quality of conversations about induction of labour (IoL) in clinical settings
Amsterdam (ots/PRNewswire) - - Almost 1 in 2 women (49%) felt the experience of IoL differed from their expectations - The majority of expectant mothers (65%) did not feel fully involved in choosing which method of IoL they prefer - Findings emphasize the importance of collaborative decision-making between ...
plusDEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
plusFDI WORLD DENTAL FEDERATION'S VIRTUAL SUMMIT ON WORLD ENVIRONMENT DAY TO HIGHLIGHT SUSTAINABLE DENTAL PRACTICES FOR A GREENER FUTURE
plus/C O R R E C T I O N -- Croma-Pharma/
Vienna (ots/PRNewswire) - In the news release, Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter, issued 09-May-2023 by Croma-Pharma over PR Newswire, we are advised by the company that the footnote [1] has been updated. The complete, corrected release follows: Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter - ...
plus
Amicogen and Lysando: Novel approach for the treatment of mastitis in dairy cows
plusSchweizerischer Nationalfonds / Fonds national suisse
The Covid-19 pandemic is preparing us for future crises
Bern (ots) - The SNSF Corona Research Conference shows how the Covid-19 pandemic has enabled us to accumulate knowledge that will be useful in dealing with future crises. "If we ever have to deal with a new pandemic in future we will not be starting from scratch, as was the case when we were confronted with the coronavirus." These are the words of scientist Barbara Rath. As an active participant in the Vienna Vaccine ...
plusHovione and H&T Presspart extend partnership to advance high efficiency device technology for Dry Powder Inhalation formulation delivery
Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that ...
plusGrünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
plusHuma and UCB partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis
New York and London (ots/PRNewswire) - - Project aims to improve patient outcomes through better clinical management of disease exacerbations using self-reported data - Exciting opportunity to improve education and empowerment and for patients to be active participants in their own care - Huma's EU MDR Class IIb ...
plusAurisco Expands Oligonucleotide Capacity and Launches New Website
SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000™ solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...
plus
Euro Airport Basel-Mulhouse-Freiburg
Annual Report 2022: a return to a stable financial position
plusAurisco Expands Oligonucleotide Capacity and Launches New Website
SETÚBAL, Portugal (ots/PRNewswire) - The New State-of-Art OligoPilot 2000TM solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs. The new website shows how R&D and Innovation is the driving force of its sustainable growth, featuring its technologies, capabilities, services and products, including Oligonucleotides, peptides and small molecules ...
plus- 3
HIN Trust Circle, now powered by SCION
plus Schweizerischer Nationalfonds / Fonds national suisse
Traffic noise - the enemy of our brains
plusInternational Society of Nephrology (ISN)
INTERNATIONAL SOCIETY OF NEPHROLOGY LAUNCHES GLOBAL KIDNEY HEALTH REPORT THAT SHEDS LIGHT ON CURRENT CAPACITY AROUND THE WORLD TO DELIVER KIDNEY CARE
Brussels (ots/PRNewswire) - Today (March 30, 2023), at the Professor Donal O'Donoghue Global Kidney Policy Forum at the World Congress of Nephrology (WCN 2023) in Bangkok, Thailand, the International Society of Nephrology (ISN) presented the highlights from its third, 2023 edition of the ISN-Global Kidney Health ...
plusBeVinced launches MedTech CRO services
Amsterdam (ots/PRNewswire) - BeVinced, a new leading Clinical Research Organization (CRO) specializing in Medical Device Regulation (MDR) compliance services, is proud to announce the launch of its services aimed at addressing the unique needs of the medical device industry. The company was started by two recognized experts in the MedTech CRO arena: Joris Bannenberg and Dirk Meijer, both MD. They founded Factory CRO in ...
plus
ALCEDIAG and SYNLAB join forces in Europe to fight diagnostic delay of bipolar disorder with the EDIT-B™ test
Paris and Milan (ots/PRNewswire) - - An estimated 2.3% of the European population is affected by bipolar disorder (BD)[1], a largely underestimated figure, since an average of 8-10 years passes between the appearance of symptoms and diagnosis[2] - To date, the diagnosis of BD is based on a psychiatric clinical ...
plusHuma receives world's first and only multi-condition EU MDR Class IIb regulatory approval for its configurable SaMD disease management platform
New York and London (ots/PRNewswire) - - Huma's platform is ready to use, reducing the time and cost for other companies to bring regulated SaMD products to market, democratising digital health innovation across the industry - Class IIb certification expands the patient population and level of disease severity that ...
plusDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
plusDEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCiTM STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
plusHovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space
Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications. The core feature of Ripple's Epidel® technology ...
plusFDI World Dental Federation calls for global leaders to prioritise action against oral diseases at major UN meeting on health / Call issued on World Oral Health Day, as data shows oral diseases impact nearly half the world's population
plus
Précédent234567891011Suivant